These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20636021)

  • 1. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
    Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
    Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
    Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
    Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice.
    Guimarães F; Guven H; Donati D; Christensson B; Ljunggren HG; Bejarano MT; Dilber MS
    Leukemia; 2006 May; 20(5):833-9. PubMed ID: 16511516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
    Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
    Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
    Locatelli F; Merli P; Rutella S
    J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
    Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
    Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study.
    Yoon SR; Lee YS; Yang SH; Ahn KH; Lee JH; Lee JH; Kim DY; Kang YA; Jeon M; Seol M; Ryu SG; Chung JW; Choi I; Lee KH
    Bone Marrow Transplant; 2010 Jun; 45(6):1038-46. PubMed ID: 19881555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
    Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of natural killer cells in hematopoetic stem cell transplantation.
    Passweg JR; Stern M; Koehl U; Uharek L; Tichelli A
    Bone Marrow Transplant; 2005 Apr; 35(7):637-43. PubMed ID: 15654351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
    Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
    Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.